X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5968) 5968
Book Chapter (107) 107
Newsletter (72) 72
Magazine Article (14) 14
Dissertation (9) 9
Book / eBook (7) 7
Newspaper Article (3) 3
Publication (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (4016) 4016
humans (3446) 3446
life sciences & biomedicine (3440) 3440
male (2089) 2089
amides - therapeutic use (1994) 1994
animals (1983) 1983
female (1805) 1805
amides (1747) 1747
amides - pharmacology (1180) 1180
pharmacology & pharmacy (1108) 1108
middle aged (1073) 1073
adult (928) 928
aged (785) 785
amides - administration & dosage (773) 773
mice (767) 767
rats (714) 714
amides - chemistry (653) 653
chemistry (611) 611
analysis (571) 571
physical sciences (568) 568
antihypertensive agents - therapeutic use (547) 547
fumarates - therapeutic use (518) 518
treatment outcome (511) 511
amides - adverse effects (465) 465
biochemistry & molecular biology (436) 436
anesthetics, local - therapeutic use (421) 421
double-blind method (414) 414
anesthetics, local - administration & dosage (398) 398
renin - antagonists & inhibitors (397) 397
dose-response relationship, drug (395) 395
hypertension - drug therapy (384) 384
science & technology - other topics (381) 381
anesthesiology (379) 379
enzymes (371) 371
pyridines - pharmacology (366) 366
antibiotics (365) 365
prospective studies (358) 358
research (356) 356
structure-activity relationship (355) 355
ropivacaine (349) 349
medicine (348) 348
research article (341) 341
time factors (336) 336
proteins (335) 335
drug therapy, combination (327) 327
multidisciplinary sciences (327) 327
pain measurement (315) 315
abridged index medicus (314) 314
chemistry, medicinal (313) 313
pain, postoperative - drug therapy (305) 305
care and treatment (301) 301
neurosciences (296) 296
hypertension (292) 292
neurosciences & neurology (291) 291
disease models, animal (283) 283
health aspects (276) 276
cardiovascular system & cardiology (273) 273
pain (268) 268
enzyme inhibitors - pharmacology (267) 267
amide (262) 262
blood pressure - drug effects (262) 262
chemistry, multidisciplinary (257) 257
aliskiren (255) 255
adolescent (252) 252
cloprostenol - analogs & derivatives (250) 250
fatty acid amide hydrolase (250) 250
cell biology (249) 249
science (249) 249
bimatoprost (247) 247
fumarates - pharmacology (246) 246
medicine & public health (244) 244
fatty acids (240) 240
surgery (237) 237
molecular structure (234) 234
drugs (233) 233
rats, sprague-dawley (226) 226
β-lactam antibiotics (225) 225
antihypertensive agents - adverse effects (224) 224
pharmacology (224) 224
amides - chemical synthesis (214) 214
microbiology (213) 213
pain, postoperative - prevention & control (213) 213
analgesics, opioid - therapeutic use (212) 212
drug resistance (210) 210
rodents (209) 209
lipids (207) 207
drug therapy (206) 206
bacteria (205) 205
physiological aspects (205) 205
aged, 80 and over (202) 202
cell line, tumor (201) 201
nerve block - methods (199) 199
renin-angiotensin system - drug effects (197) 197
cells, cultured (196) 196
amides - pharmacokinetics (195) 195
organic chemistry (194) 194
peripheral vascular disease (192) 192
rho-associated kinases - antagonists & inhibitors (187) 187
anandamide (186) 186
studies (184) 184
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5765) 5765
German (151) 151
French (74) 74
Russian (68) 68
Japanese (61) 61
Italian (59) 59
Spanish (51) 51
Portuguese (39) 39
Chinese (25) 25
Polish (11) 11
Romanian (9) 9
Turkish (6) 6
Czech (4) 4
Ukrainian (4) 4
Danish (2) 2
Norwegian (2) 2
Slovak (2) 2
Croatian (1) 1
Dutch (1) 1
Hebrew (1) 1
Hungarian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Postgraduate Medical Journal, ISSN 0032-5473, 12/2016, Volume 92, Issue 1094, pp. 726 - 734
An estimated 5.1 million Americans have chronic heart failure and this is expected to increase 25% by 2030. Heart failure is a clinical syndrome that evolves... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Vasodilator Agents - therapeutic use | Erythropoietin - therapeutic use | United States | Humans | Calcium Channel Blockers - therapeutic use | Heart Failure - physiopathology | Aminobutyrates - therapeutic use | Cardiotonic Agents - therapeutic use | Societies, Medical | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Isosorbide Dinitrate - therapeutic use | Cardiology | Platelet Aggregation Inhibitors - therapeutic use | Digoxin - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Hematinics - therapeutic use | Fumarates - therapeutic use | Anticoagulants - therapeutic use | Amides - therapeutic use | Antihypertensive Agents - therapeutic use | Evidence-Based Medicine | Heart Failure - drug therapy | Mineralocorticoid Receptor Antagonists - therapeutic use | American Heart Association | Stroke Volume | Cardiovascular Agents - therapeutic use | Hydralazine - therapeutic use | Atrial Natriuretic Factor - therapeutic use | Iron - therapeutic use | Benzazepines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Diuretics - therapeutic use | Tetrazoles - therapeutic use | Peptide Fragments - therapeutic use | Angiotensin Receptor Antagonists - therapeutic use | Drug Combinations | Practice Guidelines as Topic | Heart failure | Care and treatment | Usage | Analysis | Americans | Diagnosis | Cardiac output | Health aspects | Evidence-based medicine | Index Medicus
Journal Article
British journal of pharmacology, ISSN 0007-1188, 06/2013, Volume 169, Issue 4, pp. 772 - 783
N-3 long chain polyunsaturated fatty acids (n-3 LC PUFAs), in particular a-linolenic acid (18:3n-3), eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic... 
in-vivo | n-3 | acylethanolamines | cannabinoid-receptor | cardiovascular-disease | amide hydrolase | rat-brain | cancer cell-lines | anandamide | arachidonoyl-serotonin | PUFA, DHA, EPA | endocannabinoid system | n‐3 | fish oil | Endocannabinoids - metabolism | Ethanolamine - therapeutic use | Neuroprotective Agents - therapeutic use | Cannabinoid Receptor Agonists - metabolism | Polyunsaturated Alkamides - chemistry | Eicosapentaenoic Acid - analogs & derivatives | Humans | Fatty Acids, Omega-3 - chemistry | Polyunsaturated Alkamides - therapeutic use | alpha-Linolenic Acid - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Cannabinoid Receptor Agonists - chemistry | Neuroprotective Agents - metabolism | Drug Delivery Systems | Receptors, Cannabinoid - metabolism | Ethanolamine - chemistry | Cannabinoid Receptor Agonists - therapeutic use | Fishes | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Dopamine - metabolism | Endocannabinoids - therapeutic use | Receptors, Cannabinoid - chemistry | Acylation | Docosahexaenoic Acids - therapeutic use | Dopamine - therapeutic use | Fatty Acids, Omega-3 - metabolism | Neuroprotective Agents - chemistry | alpha-Linolenic Acid - analogs & derivatives | Ethanolamine - metabolism | Eicosapentaenoic Acid - metabolism | Polyunsaturated Alkamides - metabolism | Docosahexaenoic Acids - analogs & derivatives | Animals | Dopamine - analogs & derivatives | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | alpha-Linolenic Acid - metabolism | Fatty Acids, Omega-3 - therapeutic use | Eicosapentaenoic Acid - therapeutic use | Seafood - analysis | Dietary Supplements | Fish Oils - chemistry | Endocannabinoids - chemistry | Docosahexaenoic Acids - metabolism | Ethanolamines | Omega-3 fatty acids | Linolenic acids | Fatty acids | Dopamine | Index Medicus | Cannabinoids 2012, Part Two | Themed Section
Journal Article
Circulation. Heart failure, ISSN 1941-3297, 11/2017, Volume 10, Issue 11
BACKGROUND: Chagas' disease is an important cause of cardiomyopathy in Latin America. We aimed to compare clinical characteristics and outcomes in patients... 
Heart failure | Hospitalization | Mortality | Latin America | Trypanosoma cruzi | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Humans | Middle Aged | Heart Failure - physiopathology | Male | Heart Failure - virology | Multicenter Studies as Topic | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Time Factors | Female | Heart Failure - mortality | Chagas Cardiomyopathy - virology | Fumarates - therapeutic use | Chagas Cardiomyopathy - mortality | Risk Factors | Ventricular Function, Left - drug effects | Kaplan-Meier Estimate | Stroke Volume - drug effects | Treatment Outcome | Amides - therapeutic use | Chagas Cardiomyopathy - complications | Heart Failure - drug therapy | Randomized Controlled Trials as Topic | Cardiovascular Agents - therapeutic use | Quality of Life | Aged | Cardiovascular Agents - adverse effects | Angiotensin Receptor Antagonists - therapeutic use | Index Medicus | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Ventricular Function | Amides/therapeutic use | Klinisk medicin | Fumarates/therapeutic use | Stroke Volume/drug effects | Chagas Cardiomyopathy/complications/mortality/virology | Angiotensin Receptor Antagonists/therapeutic use | Cardiovascular Agents/adverse effects/therapeutic use | Heart Failure/drug therapy/mortality/physiopathology/virology | Clinical Medicine | Left/drug effects
Journal Article
Hypertension (Dallas, Tex. 1979), ISSN 0194-911X, 02/2007, Volume 49, Issue 2, pp. 276 - 284
Thiazide diuretics, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers all cause reactive rises in plasma renin activity. We... 
Hypertension | Aliskiren | Renin inhibitor | Renin-angiotensin-aldosterone system | Combination therapy | Plasma renin activity | Ambulatory blood pressure measurement | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Angiotensin II Type 1 Receptor Blockers - adverse effects | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Biphenyl Compounds - adverse effects | Amides | Hypertension - drug therapy | Male | Sodium Chloride Symporter Inhibitors - adverse effects | Sodium Chloride Symporter Inhibitors - therapeutic use | Biphenyl Compounds - therapeutic use | Hypertension - blood | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Aged, 80 and over | Adult | Female | Blood Pressure - drug effects | Ramipril - therapeutic use | Drug Therapy, Combination | Hypertension - diagnosis | Ramipril - adverse effects | Hydrochlorothiazide - adverse effects | Fumarates - therapeutic use | Fumarates - adverse effects | Antihypertensive Agents - therapeutic use | Renin - blood | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Antihypertensive Agents - blood | Fumarates - blood | Renin - antagonists & inhibitors | Tetrazoles - therapeutic use | Aged | Patient Compliance | Tetrazoles - adverse effects | Blood Pressure Monitoring, Ambulatory | Hydrochlorothiazide - therapeutic use | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 04/2015, Volume 385, Issue 9976, pp. 1428 - 1435
Journal Article